164 related articles for article (PubMed ID: 25005131)
1. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity.
Parra-Salcedo F; Contreras-Yáñez I; Elías-López D; Aguilar-Salinas CA; Pascual-Ramos V
Arthritis Res Ther; 2015 Feb; 17(1):34. PubMed ID: 25889060
[TBL] [Abstract][Full Text] [Related]
3. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M
Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Curtis JR; John A; Baser O
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
[TBL] [Abstract][Full Text] [Related]
5. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
6. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
[TBL] [Abstract][Full Text] [Related]
7. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.
Park YB; Choi HK; Kim MY; Lee WK; Song J; Kim DK; Lee SK
Am J Med; 2002 Aug; 113(3):188-93. PubMed ID: 12208376
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis.
Galarza-Delgado DA; Azpiri-Lopez JR; Colunga-Pedraza IJ; Cárdenas-de la Garza JA; Vera-Pineda R; Wah-Suárez M; Arvizu-Rivera RI; Martínez-Moreno A; Ramos-Cázares RE; Torres-Quintanilla FJ; Valdovinos-Bañuelos A; Esquivel-Valerio JA; Garza-Elizondo MA
Rheumatol Int; 2017 Sep; 37(9):1507-1511. PubMed ID: 28681250
[TBL] [Abstract][Full Text] [Related]
9. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
10. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
[TBL] [Abstract][Full Text] [Related]
11. Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era.
Galicia-Hernández G; Parra-Salcedo F; Ugarte-Martínez P; Contreras-Yáñez I; Ponce-de-León A; Pascual-Ramos V
Clin Exp Rheumatol; 2016; 34(2):261-9. PubMed ID: 26939612
[TBL] [Abstract][Full Text] [Related]
12. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
[TBL] [Abstract][Full Text] [Related]
13. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
García-Gómez C; Nolla JM; Valverde J; Narváez J; Corbella E; Pintó X
Eur J Clin Invest; 2008 Sep; 38(9):686-92. PubMed ID: 18837746
[TBL] [Abstract][Full Text] [Related]
14. Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs.
Contreras-Yáñez I; Rull-Gabayet M; Vázquez-Lamadrid J; Pascual-Ramos V
Eur J Radiol; 2011 Aug; 79(2):e52-7. PubMed ID: 21477956
[TBL] [Abstract][Full Text] [Related]
15. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
Schimmel EK; Yazici Y
Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
[TBL] [Abstract][Full Text] [Related]
16. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.
Contreras-Yáñez I; Pascual-Ramos V
Arthritis Res Ther; 2015 Jul; 17(1):177. PubMed ID: 26162892
[TBL] [Abstract][Full Text] [Related]
17. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.
Filippatos TD; Derdemezis CS; Voulgari PV; Tsimihodimos V; Elisaf MS; Tselepis AD; Drosos AA
Scand J Rheumatol; 2013; 42(3):169-75. PubMed ID: 23311768
[TBL] [Abstract][Full Text] [Related]
18. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.
Chen DY; Chen YM; Hsieh TY; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2015 Mar; 17(1):52. PubMed ID: 25889426
[TBL] [Abstract][Full Text] [Related]
19. Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs.
Contreras-Yáñez I; Rull-Gabayet M; Pascual-Ramos V
Clin Exp Rheumatol; 2012; 30(3):402-8. PubMed ID: 22510514
[TBL] [Abstract][Full Text] [Related]
20. The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia.
Park YJ; Yoo SA; Lee JH; Chung YJ; Cho CS; Kim W-
Clin Exp Rheumatol; 2013; 31(2):180-8. PubMed ID: 23190940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
